Tirzepatide and Calcitonin: What 12 Weeks of Data Show

TL;DR: Tirzepatide raised serum calcitonin by a mean of ~0.5 pg/mL over 12 weeks, a statistically significant but clinically negligible change; no participant crossed the 20 pg/mL investigational threshold, and no thyroid pathology was detected on ultrasound.

Abstract

Purpose: To evaluate whether short-term treatment with tirzepatide, a dual GIP/GLP-1 receptor agonist, is associated with measurable changes in serum calcitonin levels in adults with obesity and no known thyroid disease.

Methods: In this prospective observational study, 58 adults (mean age 47.5 ± 10.7 years; 72% female; mean BMI 41.4 ± 8.1 kg/m²) initiated tirzepatide therapy for weight loss. Serum calcitonin concentrations were measured at baseline and after 12 weeks of treatment. Secondary parameters included HbA1c and estimated glomerular filtration rate (eGFR).

Results: Mean baseline calcitonin was 2.7 ± 3.0 pg/mL, increasing to 3.2 ± 3.7 pg/mL post-treatment. This change was statistically significant (Wilcoxon Z = −3.0, p = 0.003) with a moderate effect size (r = 0.4), despite a small absolute increase. No participant exceeded the clinical calcitonin threshold of 20 pg/mL. No thyroid nodules were detected on ultrasound.

Conclusion: Tirzepatide treatment over 12 weeks was associated with a modest but statistically significant increase in serum calcitonin levels in adults with obesity. Absolute values remained within the normal range, and no clinically relevant thyroid abnormalities were observed. These findings support the short-term safety of tirzepatide in appropriately selected patients without known thyroid disease or risk factors for medullary thyroid carcinoma.

Study-at-a-Glance

Study Snapshot

Study Facts Table

What Researchers Actually Did

Between December 2024 and February 2025, investigators at nine outpatient endocrinology clinics in Greece recruited consecutive adults with BMI ≥ 30 kg/m² who were initiating tirzepatide for weight loss. Exclusion criteria were strict: personal or family history of MTC, known thyroid nodular disease, MEN2, or eGFR below 30 mL/min/1.73 m². Of 67 screened patients, nine were excluded (one with MTC history, eight with thyroid nodular disease), leaving 58 evaluable participants. All 58 completed the 12-week follow-up period, yielding no attrition loss. Tirzepatide was administered subcutaneously once weekly, beginning at 2.5 mg and titrated to a maximum of 5 mg per tolerability. Serum calcitonin was measured at baseline and at week 12 using electrochemiluminescence immunoassay (ECLIA) on a Cobas e411 analyzer (Roche Diagnostics) under consistent fasting, preanalytical conditions at a single certified laboratory.

Because calcitonin values were non-normally distributed (confirmed by Kolmogorov-Smirnov testing), the Wilcoxon signed-rank test was used to compare pre- and post-treatment levels, and effect size was expressed as r. Thyroid ultrasound was performed, and secondary laboratory parameters at baseline included HbA1c and serum creatinine (used to calculate eGFR via CKD-EPI). Confounding variables including smoking status, proton pump inhibitor use, gastrointestinal comorbidities, TSH, and thyroid autoantibodies were not collected and therefore could not be adjusted for in the analysis.

Key Findings: Primary Outcomes

• Calcitonin increased from 2.7 ± 3.0 to 3.2 ± 3.7 pg/mL over 12 weeks (absolute mean increase ~0.5 pg/mL; Wilcoxon Z = −3.0, p = 0.003).
• Effect size was moderate (r = 0.4), which the authors characterize as a mild pharmacological effect of uncertain clinical significance given the small absolute change.
• No participant exceeded 20 pg/mL, the lower boundary of clinically accepted investigational thresholds for MTC concern (sex- and assay-dependent range: 20–30 pg/mL). The post-treatment maximum observed was 17.2 pg/mL.
• No thyroid nodules were identified on ultrasound, and no participant reported symptoms suggestive of C-cell pathology.
• Calcium-stimulated calcitonin testing was not clinically indicated in any participant.

Key Findings: Secondary Outcomes and Subgroup Analyses

• No correlation between weight-loss magnitude and calcitonin change was observed (Spearman r = −0.07, p = 0.61), making weight reduction itself an unlikely direct mediator of the calcitonin rise.
• Baseline glycemic control was in the non-diabetic range (mean HbA1c 5.6 ± 0.4%), and renal function was preserved (mean eGFR 113 ± 47.2 mL/min/1.73 m²); no post-treatment values for these parameters were reported.
• No formal subgroup analyses by sex, age, or BMI were reported. Individual-level trajectory data (Figs. 3–4 in the paper) show heterogeneous responses: most participants had minimal change, but a subset showed larger rises that remained within the normal range.

Results: Adverse Events and Safety Profile

No adverse thyroid events were recorded. No MTC was diagnosed. No new thyroid nodules appeared on ultrasound during the 12-week observation window. No calcitonin values breached the 20–30 pg/mL threshold that would prompt calcium-stimulation testing per standard guidelines. Systemic adverse events from tirzepatide (e.g., gastrointestinal effects) were not reported or tabulated in this study, which focused exclusively on calcitonin and related thyroid endpoints.

Statistical Approach and Rigor

The choice of the Wilcoxon signed-rank test was appropriate given the non-normal distribution of calcitonin values, confirmed prospectively by the Kolmogorov-Smirnov test. Reporting an effect size (r = 0.4) alongside the p-value is commendable and prevents misinterpretation of statistical significance as clinical relevance. However, no a priori sample size calculation was performed, meaning the study was not prospectively powered to detect a specific clinically meaningful difference. The effect size was calculated post hoc, which limits interpretive weight. The absence of a control arm means regression to the mean cannot be excluded as a partial explanation for the observed shift. Correlation between weight loss and calcitonin change was assessed using Spearman’s rho, an appropriate non-parametric choice. No multivariable adjustment was attempted, and several biologically plausible confounders (TSH, thyroid autoimmunity, smoking, proton pump inhibitor use, serum calcium) were neither measured nor controlled.

Clinical Takeaway

In a carefully screened population without pre-existing thyroid disease, 12 weeks of tirzepatide at doses up to 5 mg weekly produced a statistically detectable but clinically negligible rise in serum calcitonin. Every value remained within the normal laboratory range, no participant approached actionable thresholds, and ultrasound showed no new pathology. For the prescribing clinician, this study neither raises a new safety alarm nor provides sufficient longitudinal depth to fully close the question. Standard pre-treatment calcitonin screening, contraindication to therapy in patients with personal or family history of MTC or MEN2, and ongoing monitoring per existing guidelines remain appropriate. This study does not supply grounds to abandon that framework, nor does it supply grounds to add monitoring beyond current standards in low-risk patients.

Clinical Bottom Line: In adults with obesity and no thyroid disease, 12 weeks of tirzepatide (up to 5 mg weekly) raises calcitonin by a mean of ~0.5 pg/mL, a change that is statistically detectable but clinically inert at the doses and duration studied.

Why This Matters Clinically

Regulatory agencies and clinicians prescribing GLP-1-based therapies have monitored calcitonin since the earliest rodent data showed C-cell hyperplasia with liraglutide. Tirzepatide adds GIP receptor agonism to that pharmacological profile, creating a genuinely novel mechanistic question: does dual receptor engagement alter the thyroid safety signal relative to GLP-1 monotherapy? This small prospective study is among the first to measure calcitonin longitudinally in tirzepatide-treated humans and to report that, at low-to-moderate doses over three months, the signal is detectable statistically but trivial clinically. That finding is consistent with the mechanistic reality that human thyroid C-cells show minimal or absent GLP-1R expression compared to rodents, a species difference that has always made direct translation of rodent MTC risk questionable. At the same time, the dose ceiling here (5 mg maximum) is well below the 10–15 mg doses at which a published meta-analysis documented larger, though still non-pathological, calcitonin elevations. The gap between this study’s dose range and clinically common maintenance dosing is a limitation clinicians should keep in mind.

CED Clinical Relevance

At CED Clinic, patients considering or actively using tirzepatide for weight management frequently ask whether the drug is “safe for the thyroid.” This study provides the most direct human calcitonin data yet for tirzepatide and supports the view that, in appropriately screened patients (no MTC history, no MEN2, no thyroid nodular disease), short-term use does not produce clinically relevant calcitonin elevation. For CED patients who require higher maintenance doses (10–15 mg), the meta-analysis data cited in this paper showing dose-dependent calcitonin increases at those levels should inform shared decision-making conversations, even though MTC was not reported in those trials either. Our approach remains: thorough pre-treatment thyroid risk assessment, adherence to existing contraindications, and periodic clinical reassessment rather than reflexive calcitonin monitoring in low-risk individuals.

Fits What We Already Know

The broader GLP-1 receptor agonist literature, as cited by this paper, establishes a consistent pattern: robust C-cell stimulation in rodents (where thyroid C-cells express GLP-1R abundantly), and minimal to absent effect in humans and cynomolgus monkeys (where GLP-1R expression on thyroid C-cells is sparse or absent). The LEADER trial of liraglutide and large-scale GLP-1R agonist trials have not demonstrated increased MTC incidence in humans. The SURMOUNT program for tirzepatide reported modest but statistically significant calcitonin increases, consistent with this study’s findings. A meta-analysis by Kamrul-Hasan et al. (2025), cited in this paper, documented dose-dependent calcitonin elevations at 10 mg (SMD 18.28%) and 15 mg (SMD 12.67%) without any MTC cases across included RCTs. The present study adds real-world observational data at lower doses (up to 5 mg) and confirms the same directional but clinically inert signal. The paper also places tirzepatide’s GIP component as a novel variable, noting that GIP signaling can induce CALC-I gene expression in human preadipocyte-derived adipocytes via PKA activation, a finding from Timper et al. (2011) that raises the possibility of extra-thyroidal calcitonin production pathways not previously implicated with pure GLP-1 agents.

What This Study Teaches Us

In plain terms: tirzepatide nudges calcitonin levels upward slightly over three months, but that nudge stays well within the zone that clinicians and laboratories consider normal. The drug does not appear to activate thyroid C-cells in a way that produces new nodules, clinical symptoms, or values requiring further investigation, at least not at doses up to 5 mg and not over 12 weeks in people without pre-existing thyroid conditions. The finding is real statistically, meaning it is unlikely to be random noise, but it is small enough that it does not translate into a recommendation to change current prescribing or monitoring practice for low-risk patients.

What It Does Not Show

• This study cannot establish whether calcitonin continues to rise, plateaus, or returns toward baseline with longer-term tirzepatide use beyond 12 weeks.
• It does not address thyroid safety at maintenance doses of 10 mg or 15 mg, the doses where meta-analytic data suggest a larger calcitonin signal.
• It does not characterize the risk in patients with pre-existing thyroid nodular disease, subclinical thyroid dysfunction, elevated thyroid autoantibodies, or genetic susceptibility to MTC; those groups were explicitly excluded.
• Without a control arm, spontaneous calcitonin variability, seasonal variation, regression to the mean, and the effect of weight loss itself on calcitonin cannot be rigorously disentangled from a drug effect.
• No post-treatment weight data were reported, preventing assessment of how much weight was actually lost.
• Gastrointestinal adverse events, changes in bone metabolism, and changes in serum or urine calcium were not measured, leaving mechanistic hypotheses about calcium-sensing receptor activation unconfirmed.

Fits the Broader Conversation

The incretin-based therapy field is expanding rapidly, and the question of thyroid safety with dual GIP/GLP-1 agonists is genuinely new territory. This study moves the field incrementally by providing prospectively collected human calcitonin data specifically for tirzepatide at low doses

Physician-Led, Whole-Person Care

A doctor who takes the time to truly understand you.

Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness

One-on-One Cannabis Guidance

Metabolic Balance

Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care

• Newsletter Signup Form

  Enter your email address to subscribe to our newsletter.
• Email Address*
  example@example.com
• Subscribe
• Should be Empty: